ADC Specialist Sinks on Safety Concerns: What Pharma Teams Need to Know

ADC Specialist Sinks on Safety Concerns: What Pharma Teams Need to Know

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept” for doctors and regulators. The safety signal raises critical questions for the ADC class and competitive landscape in blood cancer.

Key Takeaways

• ADC Therapeutics shares fell >50% after a confirmatory Phase 3 trial of Zynlonta in non-Hodgkin lymphoma showed higher death rates versus the control arm, a safety signal one analyst called “difficult to accept” for both clinicians and regulators.
• The most common ADC-related adverse events — peripheral sensory neuropathy (42%), nausea (35%), fatigue (34%), and neutropenia (19%) — underscore the importance of rigorous safety due diligence across the class, especially as new infection risks emerge.
• For business development and strategy teams, this event is a benchmark for reassessing risk tolerance in ADC assets targeting hematologic malignancies, with full data disclosures likely to shape regulatory and prescribing behavior.

What happened at ADC Therapeutics?

On June 4, 2026, ADC Therapeutics announced that its blood cancer drug Zynlonta met the primary endpoint in a confirmatory Phase 3 trial for non-Hodgkin lymphoma. But the topline data came with a warning flag: the study recorded more deaths in the Zynlonta arm than in the control group. Shares fell more than 50% in premarket trading, and at least one analyst said the death rate “may be difficult to accept” for doctors and regulators, according to Reuters coverage of the event.

The trial evaluated Zynlonta in relapsed or refractory non-Hodgkin lymphoma, a setting where physicians already weigh efficacy against tolerability. Antibody-drug conjugates (ADCs) are a class of drugs designed as a targeted therapy for treating disease, but at the moment are widely used for the management or treatment of cancer. The anticipated safety concern for anti-cancer ADCs during early technology development was on-target, i.e., target-mediated, toxicity, as detailed in an NIH review of ADC toxicity mechanisms.

What are the implications for pharma teams?

For business development and strategy teams, this safety signal is a live case study in ADC risk. The most common therapeutic-related adverse events of any grade, compiled in the same NIH review, include peripheral sensory neuropathy (42%), nausea (35%), fatigue (34%), neutropenia (19%), diarrhea (18%), pyrexia (14%), vomiting (13%), arthralgia (12%), pruritus (12%), myalgia (11%), peripheral motor neuropathy (11%), and alopecia (10%). These numbers frame the baseline toxicity burden that any new ADC must improve upon.

The death rate in the Zynlonta trial may prompt regulators to require additional monitoring or restrict the label, limiting commercial reach. Separately, researchers at UC Irvine found that some ADC therapies were linked to dangerously low infection-fighting white blood cell counts and related complications, as reported in a June 2026 study, adding another layer of safety diligence for developers and prescribers.

Competitors developing ADCs for hematologic malignancies should reassess their own safety data packages and communication strategies. Investors should watch for full data disclosures and any impact on ADC Therapeutics’ pipeline and existing partnerships. For BD teams evaluating ADC assets, this event reinforces the need to stress-test safety signals in both early and late-stage programs, particularly around infection risks and overall survival trends.

Frequently Asked Questions

Related profiles

• ADC Therapeutics

Related coverage

• Abivax Ulcerative Colitis Drug Shows Strong Efficacy, But Cases of Cancer Raise Concerns
• FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug: Implications for SCD Pipeline and BD Strategy
• Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg